Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2020 | CheckMate-743 study in mesothelioma

Dean Fennell, PhD, FRCP, of the University Hospitals Of Leicester NHS Trust, Leicester, UK discusses the result of the CheckMate-743 study (NCT02899299) which evaluated the efficacy of nivolumab combined with ipilimumab versus pemetrexed and cisplatin or carboplatin as first line therapy in unresectable pleural mesothelioma patients. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).